Helsinn has announced that on February 19th, the journal The Lancet Oncology published the results from the pivotal ROMANA Phase...
Helsinn has announced that ONO 7643 (anamorelin) significantly increased lean body mass (LBM) compared with placebo in two Phase III...
The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for ONO 7643 (anamorelin HCI), from...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing...
Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYLYNK-006 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with maintenance Lynparza, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
Actimed Therapeutics Ltd ,a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that it has received approval from the FDA for its IND application for one Phase IIb/III clinical study of S-pindolol benzoate (the “IMPACT” clinical trial programme) to treat cachexia associated with colorectal cancer (IMPACT CRC) and another in patients with non-small cell lung cancer (IMPACT NSCLC)
A randomised, double-blind, Phase III non-inferiority trial of 400 patients with advanced Non-Small-Cell Lung Cancer showed that Conmana (icotinib), from...
Results from the FLAURA2 Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) with the addition of chemotherapy, provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) .
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer.
EQRx, Inc. a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase III studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology.